1American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care, 1995,18 ( 11 ): 1510-1518.
2Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med, 1998,15 (4) :290-296.
3Haffner SM, Miettinen H, Stem MP. The homeostasis model in the San Antonio heart study. Diabetes Care, 1997,20(7) :1087-1092.
4Sa JR, Silva RC, Nasri F,et al. Non-obese adult onset diabetes with oral hypoglycemic agent failure:islet cell auto antibodies or reversible beta cell refractoriness. Braz J Med Biol Res, 2003,36 ( 10 ):1301-1309.
5Kosaka K, Kobayashi T,Nakanishi K, et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet patients with clinical features of NIDDM. Diabetes,1996,45 ( 5 ) :622-626.
6Rasmussen SB, Sorensen TS, Hansen JB, et al. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta cell function and mass in acutely diabetic BB rats. Horm Metab Res,2000,32(7) :294-300.
